Back to results
US 2016/0235841 A1Published application
Fgf modulation of in vivo antibody production and humoral immunity
OwnerAndrew B. Bushinventor
Life of this patent
Estimating the term…
Abstract
The invention provides methods for increasing or decreasing antibody production in vivo by inhibiting or promoting the activity of fibroblast growth factor-2 (FGF2) respectively.
Claims7
A method for increasing humoral immune response to vaccination with an immunogen in a mammal, comprising:
- in conjunction with the vaccination of a mammal to an immunogen which is other than FGF2 and other than a fibroblast growth factor receptor, inhibiting the activity of FGF2 in the mammal by administering a protein comprising a soluble receptor sequence that binds FGF2 to the mammal, thereby increasing the humoral immune response to the immunogen.
A method for increasing endogenous antibody production in a mammal, comprising:
- inhibiting the activity of FGF2 in a mammal in need of increased endogenous antibody production by administering a protein comprising a soluble receptor sequence that binds FGF2 to the mammal,
- wherein the mammal does not have a cancer.
Dependencies are inferred from the claim text.